Tranexamic acid (TXA) is an established antifibrinolytic therapy in the management of severely injured trauma patients with hemorrhage, demonstrating a proven effect on mortality reduction. Its mechanism of action is based on the inhibition of plasminogen activation, thereby stabilizing fibrin clot formation and limiting the progression of trauma-induced coagulopathy. Contemporary evidence consistently indicates that the clinical efficacy of TXA is highly time-dependent. The greatest reduction in mortality is achieved when administration is initiated early after injury, particularly within the first 3 hours, while delayed treatment is associated with a substantial loss of clinical benefit. Prehospital administration is additionally linked to improved outcomes, emphasizing the importance of minimizing time to treatment delivery within emergency care systems. Pharmacokinetic and clinical data indicate that TXA achieves effective plasma concentrations rapidly, with intravenous administration remaining the standard due to its predictable bioavailability and precise dosing capability. Meta-analyses and systematic reviews confirm a reduction in mortality without a consistent increase in overall adverse events, although heterogeneous data regarding thromboembolic complications warrant further evaluation.

Observed variability in dosing regimens and clinical implementation highlights the lack of standardized protocols and underscores the need for further stratification of patients and harmonization of treatment strategies. The administration of TXA can therefore be considered a highly effective but time-sensitive intervention, whose full therapeutic potential depends on timely and system-integrated administration within trauma care systems.

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.